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The expense of new therapies for Hepatitis C Virus (HCV) infection may force health systems to prioritise the treatment of 
certain patient groups over others. Our objective was to forecast the population impact of possible prioritisation strategies for 
the resource-rich setting of Scotland. 
DESIGN: We created a dynamic markov simulation model to reflect the HCV infected population in Scotland. We 
determined trends in key outcomes (e.g. incident cases of chronic infection, and Severe Liver Morbidity (SLM)) until the 
year-2030, according to treatment strategies involving prioritising, either: a) persons with moderate/advanced fibrosis, or b) 
Persons Who Inject Drugs (PWID). 
RESULTS: 
Continuing to treat the same number of patients with the same characteristics, will give rise to a fall in incident infection 
(from 600 cases in 2015, to 440 in 2030) and a fall in SLM (from 195 cases in 2015 to 145 in 2030). Doubling treatment-
uptake and prioritising PWID will reduce incident infection to negligible levels (<50 cases per year) by 2025, whilst SLM 
will stabilise (at 70-75 cases per year) in 2028. Alternatively, doubling the number of patients treated, but prioritising instead 
persons with moderate/advanced fibrosis will reduce incident infection less favourably (only to 280 cases in 2030), but SLM 
will stabilise by 2023 (i.e. earlier than any competing strategy). 
CONCLUSION:  
Prioritising treatment uptake among PWID will substantially impact incident transmission -however, this approach foregoes 
the optimal impact on SLM. Conversely, targeting those with moderate/advanced fibrosis has the greatest impact on SLM 
but is suboptimal in terms of averting incident infection.  








What is already known? 
1) Hepatitis C virus infection affects in excess of 140 million persons globally, and causes half a million deaths each 
year. 
2) A new era of highly effective and tolerable therapy is imminent for resource-rich settings.  
3) However, new treatments will be costly, and patient demand will likely exceed what health systems can afford to 
supply. 
4) Health systems may need to consider prioritising certain patient groups over others. 
What this study adds? 
1) Treatment strategies that prioritise Persons Who Inject Drugs (PWID) have the optimal impact on averting incident 
chronic infection, but fall short in terms of limiting new cases of Severe Liver Morbidity (SLM). 
2) Conversely, strategies prioritising persons with more advanced liver fibrosis have the most advantageous impact 
on SLM, but are suboptimal in terms of curtailing incident transmission.  
3) A trade-off between these competing impacts (curtailing SLM or curtailing incident infection) must be reached. 
How might it impact on clinical practice in the foreseeable future? 
1) To fully profit from new therapies, policy makers should consider which population goals they value most (i.e. 











Globally, in excess of 140 million persons are chronically infected with the hepatitis C virus (HCV) [1]- an infection that 
leads to half a million deaths each year from liver cirrhosis and liver cancer.[2]. A course of Pegylated Interferon and 
Ribavirin (PIR), permanently clears the infection in 50-60% of instances, and has been available to patients in resource-rich 
countries for more than a decade [3]. Yet, owing to significant adverse effects [4, 5] and a high rate of contraindication [6], 
PIR uptake has been inadequate (only 0.5-4.6% of viremic cases is treated each year [7]). Accordingly, over the last decade, 
we have seen little curtailment in HCV-related sequelae. On the contrary, HCV-related mortality is rising, and de-facto, 
more people now die from HCV than from HIV in resource rich settings such as the UK and the US [8, 9]. By this token 
then, PIR has proven an ineffective means of managing the HCV infection burden. 
It is highly significant then, that we stand today, at the cusp of a pharmacological revolution [10-12]. From 2015, HCV 
therapy will entail higher response rates, fewer contraindications, shorter durations, and greater tolerability (i.e. for most 
patients, interferon will be dispensed with altogether, and for the rest, used sparingly). With these patient-friendlier 
attributes, demand for treatment will conceivably reach unprecedented heights. But will health services be able match this 
demand with supply? HCV antiviral therapy is not cheap; the current going rate, which new therapies are likely to exceed, 
stands at ~US$100,000 per treatment course [13]. So, with in excess of 250,000 persons living with chronic infection in the 
UK alone [14], clearly we cannot afford, at least immediately, to treat everyone. Now then is a provident time to consider 
possible post-2015 national treatment strategies, in terms of their expected population-level impact.  
In most resource-rich settings (in particular, Western Europe, North America, and Australia) HCV transmission is driven by 
intravenous drug use [15]. Perhaps not surprisingly then, Treatment-To-Prevent (TTP) –  i.e. concentrating treatment 
resources on Persons Who Inject Drugs (PWID) - is attracting support [16-19]. The appeal is simple: treating a PWID 
benefits not just that individual (i.e. in terms of minimising their risk of liver complications) but the wider PWID population 
as a whole (i.e. by preventing that individual from transmitting the infection to their future injecting partners). But, by 
necessity, TTP targets a younger population, not in great danger of progressing to symptomatic liver disease (in the near 
future at least).  With the continuing rise in HCV-related mortality, an alternative approach might be, to instead set our sights 
on treating those with the highest risk of near-term liver morbidity.  
The principal of distributive justice holds that when “determining the appropriate level of health care to make available for 
one set of patients, we must take account of the effect of such a use of resources on other patients”[20]. With this in mind, 
we forecast population-level trends in a resource-rich setting, according to possible national treatment strategies. Our aim is 
to stimulate discussion as to how we can capitalise on the opportunities (whilst avoiding any ethical pitfalls) that new 




GENERAL MODEL OVERVIEW 
To forecast population-level outcomes according to alternative treatment strategies, we created a dynamic Markov model. 
The model has a compartmental structure, with each compartment representing a pertinent health state (as per the known 
natural history of HCV infection and disease progression; see eFig.1). Scotland was chosen as the setting for this model 
given her rich data sources; in particular, Scotland has a national HCV diagnosis database [21], electronically linked to a 
national HCV treatment database [22], and conducts regular epidemiological surveys of her PWID population (to note, 
throughout this paper, the “PWID” acronym refers specifically to on-going injecting drug use). [23].We drew upon these 
data sources in order to estimate the number of Scottish persons residing in each model compartment in the year 2009 (See 
Table.1 and Appendix A). Then, we used inter-compartment transfer rates obtained from the scientific literature (outlined in 
Table.2), to project liver-related disease/deaths and incident transmission over a twenty year timeframe (i.e. 2010-2030), in 
the context of interferon-free/sparing treatment regimens, available from 2015-onwards [10-12]. 
DETAILED MODEL OVERVIEW 
INCIDENT INFECTION 
The model incorporates an inflow of new injecting initiates each year (entry via PWID states; see eFig.1). The number of 
subjects entering PWID states equals the number exiting (where exit occurs through death or through ceasing injecting); 
hence, an implicit assumption underpinning this model is a stable PWID population size (i.e. ~15,300 persons[24]), in 
Scotland, over the timeframe of this model. The hallmark of PWID states is that uninfected subjects risk acquiring chronic 
infection with genotype 1-3 HCV (N.B. genotypes 4-6 account for <1% of infections in Scotland [25], and thus, for 
simplification, were omitted from this model). We assumed that PWID mix randomly, regardless of their HCV infection 
status, and so we model incident chronic infection using a mass-action transmission function [26].We calibrated this 
transmission function to an estimate of 600 incident chronic infections (95% CI: 400-800) – equating to an incidence of 10 
(7-14) per 100 person years – occurring in the year-2009 among all PWID in Scotland [27]; see appendix B for further 
details. The average injecting “career” is 9.1 years (i.e. an 11% per-annum chance of cessation) [17]. Upon ceasing injecting 
drug use, model subjects transfer permanently to former/never PWID states where incident HCV transmission no longer 
occurs (see eFig.1).  
LIVER DISEASE PROGRESSION 
Model subjects differ according to the extent of fibrosis incurred to their liver (as per the Ishak score [28]: Ishak 0-1=mild 
fibrosis; Ishak 2-5=moderate; and Ishak 6=compensated-cirrhosis). Under chronic infection, fibrosis advances from a mild to 
moderate severity at a rate of 1.8% per annum; then from moderate severity to compensated-cirrhosis at a rate of 2.7% per 
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annum (see Appendix C.1 for derivation). On average, these progression rates equate to 7% of persons developing cirrhosis 
within 20 years of initial infection (consistent with community-level observational data [29]; as is appropriate in a 
population-level model [30]). Subjects with compensated-cirrhosis are at risk of developing decompensated cirrhosis 
(defined as ascites, bleeding varices, jaundice or encephalopathy) and liver cancer. These two Severe Liver Morbidity (SLM) 
states carry a marked risk of a liver-related death (43% per annum with liver cancer; 13% per annum with decompensated 
cirrhosis [31]). Although this bleak prognosis can be improved through liver transplantation, suitable donors are scarce 
(hence our model incorporates only a 2% chance, per annum, of transplantation [32]). Of those that do receive a transplant, 
85.6% survive the first year; thereafter the risk of a liver death falls to 4.4% [32]. Patients with chronic infection and 
compensated liver disease are eligible for antiviral treatment.  Those attaining the optimal treatment outcome (a sustained 
viral response [SVR], defined as testing undetectable for viral RNA at least six months after terminating treatment) move 
into “Treatment-induced viral clearance” states and exhibit an improved prognosis vis-à-vis risk of subsequent liver disease 
progression (See eFig.1). In post-SVR Ishak-6 states, decompensated cirrhosis and liver cancer occur at a diminished rate 
(the per annum risk of decompensated cirrhosis falls from 6.5% to 0.8%; the risk of liver cancer falls from 1.4% to 0.4%). 
Subjects in post-SVR Ishak 0-5 states can still advance through to cirrhosis (Ishak 6), but at a far-reduced rate relative to 
their chronic counterparts (see Appendix C.2). Of note, we assume SVR does not benefit PWID apropos re-infection risk and 
the subsequent chance of spontaneous clearance. Finally, at every stage of the model, death from non-liver related causes 
occurs at a rate of 1.8% [33] and 1.4% per annum, in PWID and former/never PWID states, respectively (see Appendix D 
regarding estimation of the latter mortality rate). 
MODELLED TREATMENT STRATEGIES 
On average, one-thousand patients have commenced a course of antiviral therapy, each year in Scotland, between 2010 and 
2013. Of these treatment initiates, an estimated 12% were PWID (10% with mild fibrosis, and 2% with moderate-advanced 
fibrosis); 49% were former/never PIWD with mild fibrosis; and 38% were former/never PWID with moderate or advanced 
fibrosis (see Appendix E). We assume treatment-uptake and patient-composition remains unchanged in 2014. From 2015 
onwards, we model eight distinct treatment strategies. The first strategy is simply a continuation of the status-quo (i.e. 
treating the same number of patients, with the same case mix, as per 2010-2014). The remaining seven are alternative 
treatment strategies, appropriate and feasible in the context of the impending IFN-free/sparing era. Each alternative strategy 
differs in terms of treatment uptake intensity, and patient case mix; see Table.3 and eTable.9   
MODELLED TREATMENT EFFICACY 
The status-quo SVR rates (via current standard-of-care – pegylated-interferon, ribavirin ± telaprevir/bocepreivr) are taken to 
continue until the end of 2014 (see Appendix F). Thereafter, we anticipate the availability of IFN-free/IFN-sparing regimens.  
For patients infected with genotypes 1-2, we surmise that these regimens will deliver SVR rates of 95% regardless of fibrosis 
stage [34-35]. Patients with genotype-3 infection will see marginally lower efficacy levels (90% for Ishak 0-5, and 80% for 
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Ishak 6 [36, 37]). Of note, in our base-case, persons that fail a course of therapy in 2010-2014 are eligible for re-treatment, 
but only with a post-2015 IFN-free/sparing regimen (and we make the simplifying assumption that the re-treatment patient 
has the same chance of an SVR as their treatment-naïve counterpart). However, persons that fail a post-2015 course of 
therapy are not considered re-treatable (although we remove this latter assumption in sensitivity-analysis 4).  
PERFORMANCE OUTCOMES: 
We considered the performance of each treatment strategy in terms of the following outcomes occurring over a short-term 
(defined as 2015-2020), medium-term (2015-2025), and long-term (2015-2030) time horizon. 
i. Number of incident cases of SLM (i.e. decompensated cirrhosis and liver cancer) among persons with past/current 
chronic HCV infection. 
ii. Number of liver-related deaths among persons with past/current chronic HCV infection 
iii. Number of incident chronic HCV infections among PWID. 
UNCERTAINTY ANALYSIS 
PROBABILITSTIC SENSITIVITY ANALYSIS 
We performed a probabilistic sensitivity analysis, to gauge total uncertainty attributable to the sampling error, inherent in our 
Table.1 parameters. This involved: (i) assigning, to each parameter an appropriate uncertainty distribution (see Table.1); (ii) 
selecting, for each parameter, a random value from this distribution; (iii) generating all specified outcomes under this unique 
set of parameter selections; and (iv)repeating this process 10,000 times. Hence, the 95% credible interval represents the 
range within which, the central 95% of these 10,000 data points lie.  
ONEWAY SENSITIVITY ANALYSES: 
We performed various one-way sensitivity-analyses (SA) to test our conclusions against uncertain assumptions. These are 









DISEASE FORECASTS ASSUMING CONTINUATION OF EXISTING S1000-SQ STRATEGY (see Fig.1): 
With the continuation of Scotland’s existing treatment strategy (i.e. S1000-SQ), liver-related deaths increase from 130 cases 
in 2015, up to 150 cases in 2020, and stabilise thereafter. New instances of SLM peak at 195 cases in the year 2015 (i.e. the 
year we assume new treatments will be introduced), then declines continuously to 145 cases in 2030. Similarly, incident 
chronic infections fall steadily from 565 cases in 2015, to 440 cases by 2030. 
PERFORMANCE OF ALTERNATIVE TREATMENT STRATEGIES (VERSUS EXISTING S1000-SQ STRATEGY) 
(I) REDUCING INCIDENT CASES OF SEVERE LIVER MORBIDITY (see Fig.1-3, and Table .4): 
Strategies prioritising persons with moderate and advanced fibrosis (i.e. S1000-ADV and S2000-ADV) exerted the 
optimal impact on SLM. Over the long-term time horizon (i.e. 2015-2030) cumulative SLM cases are 36.1% lower 
(95% CI: -41.4 to -23.4) with S2000-ADV, than under S1000-SQ.   PWID-focused strategies also reduce SLM, but to a 
lesser extent; for example, analogously, S2000-PWID leads to a 26.2% reduction (95% CI: -32.3 to -14.7). A no-
prioritisation approach increases the number of SLM cases, relative to a status-quo case mix. In-fact, in the long-term, 
treating 2000 patients a year without prioritisation, had an equivalent impact on SLM as treating half that number under 
a fibrosis prioritising strategy. That is to say, incident SLM was 11.4% lower (95% CI: -17.9 to +27.7) under S2000-
NP, but 12.8% lower (95% CI: -19.8 to-6.8) with S1000-ADV. Notably, SLM does not decline indefinitely towards 
zero. For example, even under our maximum S2000-ADV strategy, SLM stabilises at 70 cases per year. Of these 70 
cases, the majority (40-45 cases per year) arise in patients who have previously attained SVR. 
(II) REDUCING LIVER MORTALITY (see Fig.1-3, and Table.4): 
Similarly, strategies targeting those with moderate and advanced fibrosis have the greatest impact on curtailing liver 
mortality, whilst a no-prioritisation approach increased liver deaths (relative to S1000-SQ). Thus performance with 
respect to liver mortality was a mirror image of performance with respect to SLM. A key difference between SLM and 
liver mortality however, is that the latter is less amenable to change than the former. Particularly, in the short-term, 
where even with the S2000-ADV strategy, only a 2.4% mortality reduction (95% CI: -5.0 to -1.5) is seen relative to 
S1000-SQ. Nevertheless, important differences do emerge thereafter; for example, over the longer term, a 21.4% 
mortality reduction (95% CI: -24.9 to -13.4) occurs with S2000-ADV, relative to S1000-SQ. (but this decline remains 
notably less than the 36.1% reduction in SLM seen under the same S2000-ADV strategy, and over the same time 
period). 
(III) REDUCING INCIDENT CHRONIC INFECTIONS (see Fig.1-3, and Table.4): 
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PWID-focused strategies bring about rapid steadfast declines in incident infection. Over the long-term, S2000-PWID 
leads to a 52.2% (95% CI: -55.9 to -23.9) reduction in incident infections relative to S1000-SQ. This performance far 
exceeds rival strategies – i.e. analogously, only a 13.3%-20.4% reduction occurred with S2000-ADV, S2000-SQ and 
S2000-NP. Of further mention, under S2000-PWID, the important public-health goal of reducing incident chronic 
infection to negligible levels (i.e. to less than 50 cases per year) is achieved in 2025. 
POST-HOC ANALYSES: 
1. COMBINATION STRATEGIES (see eTable.7-8, eFig.2-3) 
Under the S2000-ADV strategy, Scotland evidently begins to run out of patients with advanced fibrosis from the 
year 2025 onwards (see eTable.10). The consequence then is that in these latter years, less than the 2000 persons 
are treated per annum in our model under this strategy. Similarly, with the S2000-PWID strategy, Scotland runs 
out of infected PWID from ~2025, and so overall, less than 2000 patients are treated each year.  Given this, we 
created a post-hoc combination strategy, whereby we first target those with advanced fibrosis in 2015-2022, and 
then change our focus to PWID in 2023-2030 (we also consider the vice-versa strategy). This combination 
approach offers an improved compromise between minimising both liver-related complications and new chronic 
infections over the 2015-2030 timeframe. 
2.        RAPID DEVASTATION OF SLM (see eTable.10) 
The S2000-ADV strategy stabilises SLM at 70-75 cases by the year 2023 (i.e. within our medium-term time 
horizon). We explored, in a post-hoc interrogation of our model, how this same reduction in SLM might be 
expedited. More specifically, we posed the following question: How many patients would Scotland need to treat 
under a moderate/advanced fibrosis prioritising strategy, in order to effect a rapid devastation of SLM? We defined 
a “rapid devastation” as reducing incident SLM to <75 cases within our short-term time horizon (2015-2020). On 
that basis, the minimum such treatment uptake necessary to achieve this goal was 3250 patients per year (i.e. a 
3.25-fold increase from existing uptake levels, which amounts to treating 1980 individuals with 








Our model demonstrates the population impact of alternative treatment strategies during the landmark era of improved 
Hepatitis C therapies. What is immediately evident from these projections is that no single approach is optimal with regard 
to all public-health relevant outcomes; in other words, each involves a trade-off. For instance, targeting PWID will have the 
most advantageous impact on disease transmission, but falls short in terms of averting overt liver disease and death. 
Conversely, prioritising patients with moderate and advanced liver disease will have the maximum impact on liver-related 
complications and liver fatalities, but is suboptimal in terms of curtailing incident transmission. In more tangible terms, by 
doubling treatment uptake and targeting PWID, we have the opportunity to reduce incident infection to negligible levels (i.e. 
< 50 cases a year) in the year 2025. On the flip-side, through likewise doubling uptake, but instead prioritising those persons 
with moderate and advanced fibrosis, we can stabilise SLM (at ~70 cases per year) by the year 2023.Thus, new therapies 
afford public-health policy makers great opportunities, but equally, pose dilemmas too. Population priorities need to be 
debated and ultimately, certain trade-offs accepted.  
In an ideal world, the most tolerable and efficacious therapies would be immediately available to every patient in want. Yet, 
in the face of finite health budgets and “sticker-shock” [38] drug prices (i.e. the reality today), some system of prioritisation, 
whereby SVR is pursued with greater urgency in some, is strategically sensible and ethically justifiable. An important 
finding from this projection model is that liver-related deaths were at their highest when no prioritisation system was in 
place. In fact, treating 2000 patients randomly (i.e. as per S2000-NP) would have less impact on liver deaths than treating 
half that number under a fibrosis-prioritising strategy (i.e. as per. S2000-ADV); see Fig.4.  Of course, prioritisation 
intrinsically means treating less of one group, in order to treat more of another.  Here, our strategies are centred on directing 
therapy away from mildly fibrotic former/never PWID. But how would a policy of shepherding treatment away from this 
low-priority group work in practice? -Particularly when there are no drawbacks of toxicity to temper demand (as has always 
been the case with HCV therapies, until now).Ultimately, the success or failure of any prioritisation approach will rest on 
whether a societal consensus can be reached as to which patients merit greatest precedence. Yet in parallel, clinicians should 
be more explicit in articulating to patients what they stand to gain from a SVR – in effect, managing expectations. Until 
recently, this has been difficult because the prognosis-improvement an SVR confers has been vague (other than perhaps 
being able to say to patients that SVR lowers the risk of liver complications and death). [39] However a recent simulation 
model, synthesising the existing literature in a novel and patient-centred way, provides clearer direction. For instance, the 
sixty-year old patient with mild fibrosis has just a 1.6% and 2.9% probability of gaining additional life years and healthy life 
years, respectively (where “healthy” is defined as being free from liver decompensation). [40] More realistic expectations 
may lead to patients making more conservative treatment choices if the benefits on offer are accepted to be modest (as has 
been noted in other areas of medicine [41]). Measured expectations are needed too, on the part of health-care policy makers. 
Our model demonstrates that new therapies, targeted at those with advanced fibrosis, can dramatically reduce and stabilise 
SLM, nevertheless it will remain, going forward, an important feature of this population. Partly, this reflects a well-noted 
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continued risk of HCC among SVR patients with moderate to advanced fibrosis. More fundamentally however, post-SVR 
SLM reflects harmful lifestyle exposures intrinsic to the general HCV infected population (i.e. 90% of HCV infections are 
acquired through injecting drug use, [42] and a history of heavy alcohol use is reported in >1/3 of persons attending 
treatment services in Scotland [43]). It is often assumed, that the entirety of liver disease occurring within the chronic HCV 
infected population, is de-facto attributable to chronic infection per se. In-fact, if one examines the health outcomes of 
persons who spontaneously resolve HCV (i.e. a group who are commensurable to chronic patients in terms of lifestyle 
exposures, but who crucially, will have harboured viral RNA for a <6 month duration) one finds here too, vastly elevated 
rates of adverse liver outcomes, relative to population controls.[44-46] Our model then, foreshadows the rise of “post-SVR” 
disease, the corollary of which is that continued engagement with this population to tackle lifestyle factors will be necessary 
to drive SLM down further, and in effect, win the wider war. To that end, no magic-bullet medicines exist; rather an age-old, 
complex web of psychosocial factors to unpick. 
Although the results of this model are intended to be illustrative, we endeavoured to build treatment strategies that were 
realistic vis-à-vis implementation at a national, or even pan-national, level. However, whilst increasing the fraction of PWID 
treated each year by 20% will be seen as achievable, the same scale-up for moderate/advanced fibrotics may be viewed as a 
greater challenge. PWID for example, conveniently attend specific sites; in particular, needle exchanges and opiate 
substitution centres. Thus, they are readily accessible to outreach initiatives - the implementation of dried-blood-spot testing 
in addiction clinics being one such case-in-point [47-49]. Moderate to advanced fibrotics, on the other hand, are a more 
diffuse population, that do not similarly gather at any one particular site. As such case-finding is more challenging. To rise to 
this challenge, we need action at both primary and secondary levels of care. For instance, at the secondary care level, 
services could prioritise specific individuals known to be at high risk of moderate/advanced fibrosis. From the Scottish 
clinical database (described previously, for example in [22]), we can identify >2,000 patients with chronic HCV who: (i) 
have attended a specialist secondary-care appointment for management of their infection, (ii) are not currently receiving 
treatment, (iii) have an APRI score >0.7 (which is indicative of moderate-advanced cirrhosis[50]), (iv) are alive (as of Nov 
2013), and (v) do not have liver decompensation or liver cancer. Targeting these individuals alone, would go some way 
towards fulfilling the treatment quotas set out in S1000-ADV and S2000-ADV. At the primary-care level, age-targeted 
testing in the GP setting[51, 52] is worth consideration (on the logic that patients with advanced fibrosis tend to be older in 
age). Further, there are many individuals, who although previously diagnosed with HCV, have never gone onto attend a 
secondary-care appointment (in Scotland, we know of 4,000 such living persons aged more than 50 years). Could primary-
care play a greater role in re-signposting these specific individuals towards therapy? Overall, our contention is that despite 
their dispersed nature, we are not powerless to increase treatment uptake in this special interest group. A recent analysis 
illustrates a steady decline in the fraction of Scottish patients with liver cirrhosis receiving therapy over the last decade. [53] 
The open question then, becomes whether in this decade, and equipped with a bolstered armamentarium, we should aspire to 
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reverse this trend. Alternatively, we may decide that the prospect of curtailing incident infection is a more worthy near-term 
priority. Clearly, a debate needs to be had.  
Our model is parameterised using observational data from the scientific literature and from Scotland’s national surveillance 
databases. It is reassuring, that our modelled outcomes are in line with observational record-linkage data on liver-related 
sequelae so far (i.e. up until 2013[14]). Yet, there are specific uncertainties and limitations of this model that we must 
underscore. Firstly, fibrosis progression rates in unselected community patients are underdetermined. Indeed, the 
overwhelming majority of what we know about the speed of fibrosis accretion emanates from individuals attending specialist 
services [54] who are unlikely to be representative of the wider general-infected population (as per the disease iceberg 
phenomenon). Secondly, the real-world efficacy of future therapies is uncertain. In our base case scenario, we assumed 
treatment is equally effective for cirrhotic and non-cirrhotic genotype 1-2 patients (based on encouraging initial trial data 
[34, 35]). For genotype 3 patients we factored in a 10% differential, yet the emergence of a large efficacy-differential 
between cirrhotic and non-cirrhotic patients could impugn a fibrosis prioritising strategy. These uncertainties must be 
monitored, and models updated accordingly as more robust data becomes emerges. Thirdly, we apply a homogeneous force 
of incident infection across our PWID population; a considerable simplification of the reality, where the risk of infection will 
vary according to numerable co-factors. The transmission aspect of our model is indeed more rudimentary than some 
contemporary models [17, 55], but is sufficient we think, to capture the broad trends and trade-offs apparent when choosing 
a TTP strategy over alternatives. A further complicating scenario that our model does not account for is a rising force of 
infection over time. This might occur if at risk individuals perceive HCV to pose a diminished threat. In other words, in the 
“treat and forget” therapeutic era, PWID may not take the same precautions to avoid infection, if it is regarded as an easily 
treated condition. This sort of attitude shift may render our projections on declining transmission overly optimistic. Injecting 
risk behaviours should be closely monitored for signs of change.  Fourthly, our model is based on the population of 
Scotland; a typical resource-rich setting where contemporary transmission is driven by injecting drug use. To note however, 
that we would not expect our results (i.e. the broad trade-offs outlined here) to extend to settings with different transmission 
profiles (namely Japan, and low-middle income countries). Fifthly, we did not consider the cost-effectiveness of the 
strategies we examined; rather, only their broad-level impact at the population level in terms of outcomes that are societally 
important. Although cost-effectiveness data would not trump this work (i.e. there is more to selecting the right treatment 
approach than simply considering the bottom line cost per QALY), it would add an important dimension, and should be a 
focus for the future. Sixth, we did not model fibrosis progression according to co-factors such as older age, male gender and 
heavy alcohol consumption, but assumed a blanket rate for all. We concede that this could introduce an important bias here 
because these co-factors accelerate fibrogenesis [56], and may be more prevalent (heavy alcohol use and older age in 
particular) among those with more advanced disease, than in competing priority groups such as PWID. Thus in reality, 
disease progression in these two groups may not occur at the same rate. In this respect, the outlined impact of prioritising 
moderate/advanced fibrotics on liver-related sequelae might be seen as conservative. Finally, although therapies capable of 
 13 
80-95% SVR rates are set to be approved by 2015, “sticker shock” prices [38] may mean they are used selectively, with 
inferior therapies continuing to be prescribed to lower priority groups (or perhaps to groups for which inferior regimens still 
offer a reasonable chance of SVR). These eventualities are not considered in our model. 
The major strength of this study lies in the combined modelling of incident infection and liver disease progression. In 
contrast, previous models have tended to consider one or the other, such that they inevitably end up arriving at one-sided 
view vis-à-vis which patient group is the treatment priority. [16, 17, 57-60]  Combining the two herein is an important 
advancement that lends crucial insight and a more complete picture for health-care policy makers. In summary, this work 
highlights the opportunities but also opportunity costs of new therapeutic advancements. Now is the provident time to 
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TABLE.1:  Parameters to populate each model compartment at inception (year-2009)  
          
Parameter/data item Symbol Mean value Data 
source 
Sampling distribution 95% credible 
interval 
    
Number of PWID in Scotland (in 2009) α 15,300 [24] Sampled from the 
posterior distribution of 
Prevost et al [24] 
13,270-17,180 
Number of PWID in Scotland with HCV antibodies (in 2009) γ 7,550 6,620-8,550 
Number of ever-PWID with HCV antibodies in Scotland (in 2009) δ 47,650 33,480-67,130 
Proportion of persons with HCV antibodies in Scotland that have ever 
injected drugs (in 2009) 
ε 85% [42] N(0.85, 0.02) 82.0-88.2 
Proportion of persons with HCV antibodies that spontaneously clear  
infection 
φ 26% [61] N(0.26, 0.018) 22.6-29.5 
Number of Scottish persons living (in 2009) with treatment-induced viral 
clearance 
η 2000 * ^ 
 
Fibrosis distribution 
in overall chronically 
infected population  
2009) 
 
PWID Mild  θ1 83.5% [32] Sampled from the 
Posterior distribution 
of Hutchinson et al 
[32] 
56.2-92.0 
Moderate  ξ1 15.4% 7.4-42.0 
Cirrhosis  Ϋ1 1.1% 0.5-2.2 
Former/never PWID Mild   θ2 55.4% 42.1-66.7 
Moderate ξ2 37.3% 27.2-50.3 
Cirrhosis Ϋ2 5.8% 4.4-7.9 
Decomp 
cirrhosis 
Ψ 1.3% 1.1-2.0 
HCC π 0.12% 0.07-0.18 
          
Genotype distribution (%) in overall chronically 
infected population (2009) 
1 
λi 




2 λ2 5.1% 4.7-5.5 
3 λ3 46.0% 45.1-46.9 
          
Fibrosis distribution 
in infected population 
receiving treatment 
(2009) 
PWID Mild θ1RX 81.1% See Appendix E 
Moderate ξ1RX 16.5% 
Cirrhosis Ϋ1RX 2.4% 
Former/never PWID Mild  θ2RX 56.0% 
Moderate  ξ2RX 26.5% 
Cirrhosis Ϋ2RX 17.5% 
          
Number of PWID treated, per annum in Scotland (2007 onwards) τ 120 [17] U (60, 180) 64-181 
  20 
Total persons treated for chronic HCV in Scotland, per annum (2009-
2013)  
µ 1000 [14] ^ 
^ Not varied, * Unpublished data from the Scottish Clinical database     
 
 
TABLE.2:  Parameters defining inter-compartment transfer rate, 2010-2030.  
          
Parameter/data item Symbol Mean value Data 
source(s) 
Sampling distribution 95% credible 
interval 




Beta (19.87, 1083.88) 1.1-2.7 
Moderate fibrosis→compensated cirrhosis (under chronic infection) (b) 2.7% Beta (14.07, 514.12) 1.4-4.2 




Beta (19.87, 1083.88) 
& Norm(0.22, 0.05) 
0.2-0.7 
Moderate fibrosis→compensated cirrhosis (post-SVR) (d) 0.6% Beta (14.07, 514.12) & 
Norm(0.22, 0.05) 
0.3-1.1 
cirrhosis →decompensated cirrhosis (under chronic infection) (e)  6.5% [32] Norm (6.5,1.3) 3.9-9.1 
cirrhosis→liver cancer (under chronic infection) (f) 1.4% [31] Beta (1.92, 135.12) 0.5-2.8 




Norm (6.5,1.3) & 
U(0.07-0.19) 
0.4-1.5 
cirrhosis/decomp cirrhosis→liver cancer (post-SVR) (h) 0.4% Beta (1.92, 135.12) & 
U (0.18, 0.46) 
0.05-1.3 
Decompensated cirrhosis→liver death (i) 13% [31] Beta (146.9, 983.1) 11.2-15.1 
HCC→liver death (j) 43.0% [31] Beta (116.67, 154.66) 37.0-48.8 
DC/HCC→liver transplant (k) 2% [32] Beta (10.18, 498.71) 0.9-3.4 
Liver transplant death in first year (l) 14.6% [32] N (14.6, 1.81) 11.0-18.2 
Liver transplant death post year 2+ (m) 4.4% [32] N (4.4, 0.46) 3.5-5.3 
Annual mortality rate former PWID/never PWID  (n) 1.4% See appendixD 
PWID  (o) 1.8% [30] N (1.8, 0.55) 0.8-2.9 
Annual probability of ceasing injecting   (p) 9.1% [33] Tri (0.05, 0.17, 9.1) 5.4-11.1 
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Risk group fibrosis distribution
PWID 10% mild; 2% moderate; <1% cirrhotic
former/never PWID 49% mild, 23% moderate, 15% cirrhotic
PWID
former/never PWID
PWID 27% mild; 5% moderate; 1% cirrhotic
former/never PWID 29% mild; 23% moderate; 15% cirrhotic
PWID
former/never PWID
PWID 10% mild; 2% moderate; <1% cirrhotic










strategies appropriate in 
a new treatment era
* Where appropriate, over the 2015-2017 period, all strategies factor in a phased/gradual transition towards the specified uptake level/case mix
Mantain s tatus  quo uptake; Treat patient groups  according to their prevalence in the 
overa l l  infected population. For example, i f in any given year, active PWIDs  represent 
20% of the total  infection pool , then 200 PWID (i .e. 20% of the 1,000 treatment quota) 
wi l l  be treated in that year. This  i s  a  hypothetica l  benchmark s trategy, broadly akin to a  
fi rs t-come-fi rs t-served dis tribution approach in an era  of universa l  diagnos is  and 
treatment demand.
Maintain s tatus-quo uptake; otherwise, as  per S1000-ADV
S1000-NP 1000
S2000-NP 2000 Double uptake; otherwise, as  per S1000-FCFS
2000 As per S1000-ADVS2000-ADV
NA
NA
Maintain s tatus-quo uptake;divert 20% of tota l  ini tiations  away  from mi ldly fibrotic 




Table 3: Post-2015 treatment strategies modelled*
Double uptake;otherwise, as  per S1000-PWID
Maintain s tatus-quo uptake;divert 20% of tota l  ini tiations  away  from mi ldly fibrotic 






Strategy description (treatment quota; case mix)
As per S1000-SQ
Maintain status-quo uptake; maintain status-quo case mix
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Table.4: Cumulative modeled number* of: (I) incident cases of Severe Liver Morbidity (II) Liver deaths and (III) incident chronic 
infections, according to treatment strategy and time horizon. 
          
Time 
Horizon 
Strategy (i) Severe Liver Morbidity 
 
(ii) Liver deaths 
 
(iii) Incident chronic infections 
Cumulative 






  Cumulative 






  Cumulative 









S1000-SQ 1140 (500, 2085) REF  845 (415, 1500) REF  3270 (1695, 5025) REF 
S1000-PWID 1135 (500, 2080) -0.4 (-0.9, 0)  845 (415, 1500) 0 (-0.7, 0)  3145 (1575, 4960) -3.8 (-7.3, -1.1) 
S1000-ADV 1100 (470, 2040) -3.5 (-7.0, -1.8)  840 (410, 1495) -0.6 (-1.5, 0)  3270 (1695, 5025) 0.0 (0.0, 0.0) 
S1000-NP 1200 (570, 2140) +5.3 (1.6, 16.5)  860 (425, 1510) +1.8 (0.4, 3.8)  3260 (1715, 5010) -0.3 (-1.8, 2.3) 
S2000-SQ 1065 (440, 1995) -6.6 (-13.6, -3.5)  835 (405, 1485) -1.2 (-2.7, -0.6)  3190 (1620, 4990) -2.4 (-4.6, -0.6) 
S2000-PWID 1060 (435, 1990) -7.0 (-14.5, -3.7)  835 (405, 1485) -1.2 (-2.8, -0.7)  2910 (1365, 4785) -11.0 (-20.5, -3.8) 
S2000-ADV 995 (390, 1910) -12.7 (-23.8, -7.0)  825 (395, 1470) -2.4 (-5.0, -1.5)  3190 (1620, 4990) -2.4 (-4.6, -0.6) 
S2000-NP 1135 (535, 2045) -0.4 (-3.9, 9.4)  845 (420, 1490) 0 (-1.0, 2.4)  3115 (1610, 4885) -4.7 (-8.5, -1.4) 





S1000-SQ 2005 (820, 3740)) REF  1605 (750, 2880) REF  5755 (2625, 9270) REF 
S1000-PWID 1995 (810, 3725) -0.5 (-1.4, -0.3)  1600 (745, 2875) -0.3 (-0.6, 0)  5080 (2025, 8935) -11.7 (-24.5, -2.7) 
S1000-ADV 1845 (700, 3560) -8.0 (-16.0, -4.4)  1555 (710, 2820) -3.1 (-5.9, -1.8)  5755 (2625, 9270) 0.0 (0.0, 0.0) 
S1000-NP 2175 (1060, 3850) +8.5 (1.8, 33.7)  1670 (825, 2930) +4.0 (1.0, 12.2)  5720 (2810, 9205) -0.6 (-3.0, 8.5) 
S2000-SQ 1685 (630, 3375) -16.0 (-25.9, -8.8)  1505 (680, 2760) -6.2 (-10.5, -3.6)  5350 (2250, 9085) -7.0 (-15.4, -1.4) 
S2000-PWID 1660 (620, 3350) -17.2 (-27.3, -9.4)  1495 (675, 2750) -6.9 (-11.1, -3.9)  3695 (1470, 7955) -35.8 (-45.1, -12.3) 
S2000-ADV 1405 (565, 3045) -29.9 (-36.1, -17.6) 1405 (645, 2635) -12.5 (-16.3, -7.2)  5350 (2250, 9085) -7.0 (-15.4, -1.4) 
S2000-NP 1915 (935, 3510) -4.5 (-10.8, 18.9)  1585 (780, 2810) -1.2 (-4.3, 6.8)  5120 (2525, 8780) -11.0 (-15.9, 0.3) 




S1000-SQ 2770 (1030, 5250) REF  2340 (1020, 4245) REF  8040 (3275, 13405) REF 
S1000-PWID 2735 (1010, 5225) -1.3 (-2.2, -0.5)  2330 (1010, 4225) -0.4 (-1.1, -0.2)  6225 (2150, 12685) -22.6 (-35.5, -3.9) 
S1000-ADV 2415 (870, 4870) -12.8 (-19.8, -6.8)  2190 (925, 4065) -6.4 (-10.4, -3.7)  8040 (3275, 13405) 0.0 (0.0, 0.0) 
S1000-NP 3045 (1510, 5450) +9.9 (1.4, 52.1)  2480 (1225, 4355) +6.0 (1.1, 23.4)  7940 (3840, 13325) -1.2 (-3.5, 20.1) 
S2000-SQ 2075 (790, 4445) -25.1 (-30.9, -13.8) 2035 (875, 3890) -13.0 (-17.2, -7.4)  6970 (2435, 13035) -13.3 (-26.3, -1.9) 
S2000-PWID 2045 (770, 4400) -26.2 (-32.3, -14.7) 2015 (865, 3865) -13.9 (-18.1, -7.9)  3845 (1555, 9910) -52.2 (-55.9, -23.9) 
S2000-ADV 1770 (720, 3735) -36.1 (-41.4, -23.4) 1840 (830, 3570) -21.4 (-24.9, -13.4) 6970 (2435, 13035) -13.3 (-26.3, -1.9) 
S2000-NP 2455 (1250, 4670) -11.4 (-17.9, 27.7)   2230 (1115, 4035) -4.7 (-9.3, 12.8)   6405 (3380, 12445) -20.3 (-21.5, 8.9) 
* rounded to the nearest five         
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